Other News To Note * SuperGen Inc., of San Ramon, Calif., was granted FDA approval to market mitomycin for injection. Originally developed and marketed by Bristol-Myers Squibb Co., of New York, under the trade name Mutamycin, the drug is approved in the U.S. for the treatment of adenocarcinoma of the stomach and pancreas, in combination with other approved chemotherapeutics. SuperGen expects to begin selling mitomycin in June.

No Comments